ScreenerHero

BIOA BioAge Labs, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · bioagelabs.com
6.210USD-0.80%Mkt Cap: 285.02M $P/E: —

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to iden…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.13BUSDP/E 24.9
TAK
Takeda Pharmaceutical Company Limited
$59.16BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.78BUSDP/E 65.4
GALD
Galderma Group AG
$43.33BUSDP/E 56.1
HLN
Haleon plc
$40.72BUSDP/E 18.9
SDZ
Sandoz Group AG
$34.23BUSDP/E 59.2
HLN
Haleon plc
$32.92BUSDP/E 19.1
ZTS
Zoetis Inc.
$30.20BUSDP/E 12.0
UTHR
United Therapeutics Corporation
$22.85BUSDP/E 19.1
VTRS
Viatris Inc.
$20.03BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.06BUSDP/E 110.0
NBIX
Neurocrine Biosciences, Inc.
$14.36BUSDP/E 20.7
IPN
Ipsen S.A.
$12.68BUSDP/E 22.9
ELAN
Elanco Animal Health Incorporated
$11.26BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.16BUSDP/E 27.7
KRK
Krka, d. d.
$8.71BUSDP/E 19.4
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1
HLUN-B
H. Lundbeck A/S
$6.66BUSDP/E 11.8
ALKS
Alkermes plc
$6.73BUSDP/E 105.6
HIMS
Hims & Hers Health, Inc.
$6.55BUSD

Key Statistics

Company
Market Cap285.02M USD
Enterprise Value-28.60M USD
Revenue (TTM)10.36M USD
Gross Profit-77.43M USD
Net Income (TTM)-80.61M USD
Revenue/Share0.26 USD
Last Price6.210 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.57
PEG—
EV/EBITDA0.27
EV/Revenue-2.76
P/S27.52
P/B0.76
EPS (TTM)-2.39
EPS (Forward)-2.41
52W Range
5.0406% of range25.95
52W High25.95 USD
52W Low5.040 USD
Profitability
Gross Margin0.00%
Oper. Margin-1196.78%
EBITDA Margin0.00%
Profit Margin-896.11%
ROE-29.63%
ROA-27.33%
Growth
Revenue Growth1.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.63M USD
CapEx (TTM)719.00K USD
FCF Margin-560.76%
FCF Yield-20.37%
Net Debt-315.91M USD
Net Debt/EBITDA2.98
Balance Sheet
Debt/Equity0.02
Current Ratio17.19
Quick Ratio16.75
Book Value/Sh8.19 USD
Cash/Share6.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)35.63 USD
Upside (mean)+473.7%
Target Range20.00 USD – 73.00 USD
20.00+473.7% to mean73.00
# Analysts8
Ownership
Shares Out.45.90M
Float39.19M
Insiders2.36%
Institutions90.61%
Short Interest
Short Ratio5.6d
Short % Float7.53%
Short % Out.6.70%
Shares Short3.07M
Short (prev mo.)2.22M
Technical
SMA 509.321 (-33.4%)
SMA 20016.58 (-62.5%)
Beta1.08
S&P 52W Chg15.84%
Avg Vol (30d)786.48K
Avg Vol (10d)981.05K
Technical Indicators
RSI (14)22.8
MACD-1.0709
MACD Signal-1.1296
MACD Hist.+0.0587
BB Upper8.988 USD
BB Middle7.385 USD
BB Lower5.782 USD
BB Width43.41%
ATR (14)0.5286 USD
Vol Ratio (20d)1.01x